LIBI-Diagnostics

A gene-biomarker startup for the early detection of cancer, powered by next-generation bio-liquid tests.

Health Tech & Life Sciences
Active
Pre-Funding Haifa, Israel Founded 2020
Last updated 2026-07-26
Total raised
Last: Undisclosed Round 2021-10
Stage
Pre-Funding
Founded
2020
Headcount
5
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

LIBI-Diagnostics is an Israeli startup focused on the early detection of cancer using gene-biomarker next-generation bio-liquid tests. The company aims to detect recurrent cancerous development at an early stage with minimal cells, providing sufficient information to neutralize early development and potentially spare patients aggressive treatments. They customize tests for each patient by detecting alterations of Aurora Kinase A in blood and/or voided urine samples compared to genomic expression data in the primary tumor. The company's vision is to make cancer an easy disease to treat through early detection, shortening treatment durations, reducing intensity, and avoiding unnecessary deaths. The venture successfully completed the MaofTech acceleration program of the Israeli Ministry of Economy and is collaborating with Albert Einstein College of Medicine in New York to develop a non-invasive method to detect and quantify AURKA gene mRNA overexpression.

Funding history · 1 round · — total

2021-09
Undisclosed Round Undisclosed
★ Headstart

Q&A

What is LIBI-Diagnostics' primary focus?
LIBI-Diagnostics is a gene-biomarker startup focused on the early detection of cancer using next-generation bio-liquid tests.
When was LIBI-Diagnostics founded?
LIBI-Diagnostics was founded in January 2020.
How many employees does LIBI-Diagnostics have?
LIBI-Diagnostics has 1-10 employees.
What technology does LIBI-Diagnostics utilize for its diagnostic tests?
LIBI-Diagnostics uses Next-Generation Sequencing (NGS) technology to detect alterations of Aurora Kinase A in blood and/or voided urine samples for cancer diagnosis.
Who are the co-founders of LIBI-Diagnostics?
The co-founders of LIBI-Diagnostics are David Risin, who serves as Co-Founder & CEO, and Dr. Ayelet Ben Barak, who is Co-founder & CMO.
What is the current stage of LIBI-Diagnostics' product development?
LIBI-Diagnostics' product is currently in the R&D stage.
What was LIBI-Diagnostics' last funding round?
In October 2021, LIBI-Diagnostics received $100,000 in a funding round led by Headstart.

Team · 4

David Risin
Founder · Co-Founder & CEO
Prof. Genjem Kalpana
Founder · Partner
Dr. Shiri Karni-Ashkenzi
Founder · Partner
Dr. Ayelet Ben-Barak
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesHealthcarePatients
Business model
B2B

Tags

cancerdiagnosticsoncologygeneticspatientsearly-detectiondoctorsnon-invasivebiomarkersdigital-healthcare
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)